2024
USPSTF Colorectal Cancer Screening Recommendation and Uptake for Individuals Aged 45 to 49 Years
Siddique S, Wang R, Yasin F, Gaddy J, Zhang L, Gross C, Ma X. USPSTF Colorectal Cancer Screening Recommendation and Uptake for Individuals Aged 45 to 49 Years. JAMA Network Open 2024, 7: e2436358. PMID: 39361285, PMCID: PMC11450516, DOI: 10.1001/jamanetworkopen.2024.36358.Peer-Reviewed Original ResearchConceptsUS Preventive Services Task ForceUS Preventive Services Task Force recommendationsColorectal cancer screening uptakeAverage-risk individualsScreening uptakeHigher socioeconomic statusSocioeconomic statusScreening recommendationsColorectal cancerColorectal cancer screening recommendationsPreventive Services Task ForceCohort studyCancer screening recommendationsScreening uptake ratesInterrupted time series analysisLow socioeconomic statusPrivate insurance beneficiariesScreening ratesSocioeconomic disparitiesRetrospective cohort studyMain OutcomesPotential disparitiesEvaluate changesClaims dataAbsolute changeActive Surveillance or Watchful Waiting for Intermediate-Risk Prostate Cancer, 2010-2020
Ajjawi I, Loeb S, Cooperberg M, Catalona W, Gross C, Ma X, Leapman M. Active Surveillance or Watchful Waiting for Intermediate-Risk Prostate Cancer, 2010-2020. JAMA 2024, 332: 2033-2036. PMID: 39565605, PMCID: PMC11579888, DOI: 10.1001/jama.2024.20580.Peer-Reviewed Original ResearchDisparities in Colorectal Cancer Screening Before and After the Onset of the COVID Pandemic
Siddique S, Wang R, Gaddy J, Stempel J, Warren J, Gross C, Ma X. Disparities in Colorectal Cancer Screening Before and After the Onset of the COVID Pandemic. Journal Of General Internal Medicine 2024, 1-9. PMID: 39495455, DOI: 10.1007/s11606-024-09153-3.Peer-Reviewed Original ResearchRisk of CRCSocioeconomic statusCRC screeningArea-level socioeconomic measuresArea-level socioeconomic factorsHigher risk of CRCArea residentsColorectal cancer screeningSocial deprivation indexHigher socioeconomic statusLow socioeconomic statusEthnic minoritized populationsDifference-in-differences analysisPost-onset periodDesignRetrospective cohort studyDeprivation indexCancer screeningSocioeconomic measuresPrivately insured individualsMetropolitan area residentsCOVID pandemicScreen useAverage riskCompare disparitiesSocioeconomic factorsAmbient Temperature and Stroke Risk Among Adults Aged 18-64 Years A Case-Crossover Study
Chu L, Wang R, Gross C, Chen K, Ma X. Ambient Temperature and Stroke Risk Among Adults Aged 18-64 Years A Case-Crossover Study. Journal Of The American College Of Cardiology 2024, 84: 2327-2331. PMID: 39453364, DOI: 10.1016/j.jacc.2024.08.058.Peer-Reviewed Original ResearchLong-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer
Kunst N, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Rabil M, Ghaffar U, Karnes R, Ma X, Gross C, Wang S, Leapman M. Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer. JAMA Network Open 2024, 7: e2440591. PMID: 39441595, PMCID: PMC11581571, DOI: 10.1001/jamanetworkopen.2024.40591.Peer-Reviewed Original ResearchConceptsProstate-specific antigenProstate-specific antigen levelPSMA-PETRecurrent prostate cancerBiochemical recurrenceProstate cancerLong-term outcomesProstate-specific membrane antigen positron emission tomographyEvaluation of biochemical recurrenceDetection of biochemical recurrenceLife yearsConventional imagingDefinitive local therapyPSMA PET imagingProstate cancer deathDetection of metastasesRetrospective cohort studyBase case analysisIncremental life-yearsPositron emission tomographyDecision-analytic modelLocal therapyConventional imaging strategiesDelayed treatmentDisease courseAssociations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer
Sundaresan V, Wang R, Long J, Sprenkle P, Seibert T, Loeb S, Cooperberg M, Catalona W, Ma X, Gross C, Leapman M. Associations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer. Urology Practice 2024, 11: 965-973. PMID: 39196719, DOI: 10.1097/upj.0000000000000679.Peer-Reviewed Original ResearchLocalized prostate cancerClinically localized prostate cancerHigh-risk diseaseProstate MRIProstate cancerTreatment intensificationIntensified treatmentGenomic testingTreated patientsProstate magnetic resonance imagingEnd Results databaseLong-term patient outcomesProstate cancer prognosisRetrospective cohort studyAssociated with decreased oddsRisk stratification toolPrimary study outcomeAssociated with increased oddsMagnetic resonance imagingResults databaseStratification toolTreatment patientsCohort studyRisk strataCancer prognosisPD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY
Leapman M, Rabil M, Ghaffar U, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Kunst N, Wang S, Ma X, Gross C, Karnes R. PD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY. Journal Of Urology 2024, 211: e971. DOI: 10.1097/01.ju.0001008792.09108.b4.10.Peer-Reviewed Original ResearchPD08-10 EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: RESULTS OF DECISION ANALYTIC MODELING
Kunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. PD08-10 EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: RESULTS OF DECISION ANALYTIC MODELING. Journal Of Urology 2024, 211: e177. DOI: 10.1097/01.ju.0001008576.33217.96.10.Peer-Reviewed Original ResearchMP57-08 COST EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) FOR THE EVALUATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER IN THE UNITED STATES HEALTHCARE SYSTEM
Kunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. MP57-08 COST EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) FOR THE EVALUATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER IN THE UNITED STATES HEALTHCARE SYSTEM. Journal Of Urology 2024, 211: e940. DOI: 10.1097/01.ju.0001009420.83948.eb.08.Peer-Reviewed Original ResearchPD45-11 TEMPORAL AND REGIONAL PATTERNS OF PROSTATE CANCER POSITRON EMISSION TOMOGRAPHY IMAGING AMONG COMMERCIAL INSURANCE BENEFICIARIES IN THE UNITED STATES
Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Karnes R, Kunst N, Wang S, Ma X, Gross C. PD45-11 TEMPORAL AND REGIONAL PATTERNS OF PROSTATE CANCER POSITRON EMISSION TOMOGRAPHY IMAGING AMONG COMMERCIAL INSURANCE BENEFICIARIES IN THE UNITED STATES. Journal Of Urology 2024, 211: e972. DOI: 10.1097/01.ju.0001008792.09108.b4.11.Peer-Reviewed Original Research‘It Just Makes Sense to Me’: A qualitative study exploring patient decision‐making and experiences with prostate MRI during active surveillance for prostate cancer
Sutherland R, Gross C, Ma X, Jeong F, Seibert T, Cooperberg M, Catalona W, Ellis S, Loeb S, Schulman‐Green D, Leapman M. ‘It Just Makes Sense to Me’: A qualitative study exploring patient decision‐making and experiences with prostate MRI during active surveillance for prostate cancer. BJUI Compass 2024, 5: 593-601. PMID: 38873351, PMCID: PMC11168777, DOI: 10.1002/bco2.351.Peer-Reviewed Original ResearchProstate magnetic resonance imagingMagnetic resonance imagingProstate cancerActive surveillanceActive surveillance of prostate cancerGleason Grade Group 1Surveillance of prostate cancerIntermediate-risk prostate cancerMonitoring of prostate cancerMRI-ultrasound fusion biopsyGrade group 1Monitoring prostate cancerGroup 2 tumorsMagnetic resonance imaging scansFusion biopsyLongitudinal follow-upProstate biopsyFollow-upProstateSemi-structured interviews of patientsMRI useQualitative studyGroup 1Interviews of patientsPatientsTemporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States.
Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Karnes R, Kunst N, Wang S, Ma X, Gross C. Temporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States. Journal Of Clinical Oncology 2024, 42: 34-34. DOI: 10.1200/jco.2024.42.4_suppl.34.Peer-Reviewed Original ResearchProportion of patientsProstate cancerPSMA-PETPET imagingProstate specific membrane antigen positron emission tomographyDiagnosis of prostate cancerProstate cancer visualizationPSMA PET imagingPSMA-targeted agentsPositron emission tomography imagingCochran-Armitage testDynamic cohort studyPositron emission tomographyCommercial insurance beneficiariesEmission tomography imagingChi-square testCancer visualizationCholine tracersCohort studyProstateTreatment decisionsBlue Cross Blue Shield AxisCochran-ArmitageEmission tomographyInsurance beneficiaries
2023
Patient experiences with tissue‐based genomic testing during active surveillance for prostate cancer
Leapman M, Sutherland R, Gross C, Ma X, Seibert T, Cooperberg M, Catalona W, Loeb S, Schulman‐Green D. Patient experiences with tissue‐based genomic testing during active surveillance for prostate cancer. BJUI Compass 2023, 5: 142-149. PMID: 38179031, PMCID: PMC10764160, DOI: 10.1002/bco2.277.Peer-Reviewed Original ResearchActive surveillanceProstate cancerGene expression testGenomic testingCancer riskPatient experienceGrade group 2 prostate cancerGleason Grade Group 1Risk prostate cancerGrade group 1Prostate cancer riskProstate cancer managementProstate cancer aggressivenessHereditary cancer riskGermline genetic testsTissue-based testsGenomic test resultsConclusions PatientsInitial biopsyPhysician recommendationPatient knowledgePatient counsellingConventional content analysisCancer managementExpression testParent Priorities in End-of-Life Care for Children With Cancer
Ananth P, Lindsay M, Mun S, McCollum S, Shabanova V, de Oliveira S, Pitafi S, Kirch R, Ma X, Gross C, Boyden J, Feudtner C, Wolfe J. Parent Priorities in End-of-Life Care for Children With Cancer. JAMA Network Open 2023, 6: e2313503. PMID: 37184834, PMCID: PMC10878399, DOI: 10.1001/jamanetworkopen.2023.13503.Peer-Reviewed Original ResearchPD10-01 ASSOCIATIONS BETWEEN PROSTATE MRI AND GENOMIC TESTING AND TREATMENT INTENSIFICATION AMONG PATIENTS WITH LOCALIZED PROSTATE CANCER
Leapman M, Wang R, Long J, Sprenkle P, Ma X, Gross C. PD10-01 ASSOCIATIONS BETWEEN PROSTATE MRI AND GENOMIC TESTING AND TREATMENT INTENSIFICATION AMONG PATIENTS WITH LOCALIZED PROSTATE CANCER. Journal Of Urology 2023, 209: e326. DOI: 10.1097/ju.0000000000003250.01.Peer-Reviewed Original ResearchPatient experiences with tissue-based genomic testing during active surveillance for prostate cancer.
Leapman M, Sutherland R, Gross C, Ma X, Jeong F, Seibert T, Cooperberg M, Catalona W, Loeb S, Schulman-Green D. Patient experiences with tissue-based genomic testing during active surveillance for prostate cancer. Journal Of Clinical Oncology 2023, 41: 333-333. DOI: 10.1200/jco.2023.41.6_suppl.333.Peer-Reviewed Original ResearchActive surveillanceProstate cancerGene expression testGenomic testingCancer riskPatient experienceGleason Grade Group 1Risk prostate cancerGrade group 1Routine clinical careProstate cancer riskGroup 2 tumorsProstate cancer managementProstate cancer aggressivenessHereditary cancer riskGermline genetic testsTissue-based testsRace/ethnicityInitial biopsyPatient knowledgeMean agePatient counselingCancer managementClinical careExpression test“It just makes sense to me”: Patient experiences with prostate MRI during prostate cancer active surveillance.
Sutherland R, Gross C, Ma X, Jeong F, Seibert T, Cooperberg M, Catalona W, Loeb S, Schulman-Green D, Leapman M. “It just makes sense to me”: Patient experiences with prostate MRI during prostate cancer active surveillance. Journal Of Clinical Oncology 2023, 41: 334-334. DOI: 10.1200/jco.2023.41.6_suppl.334.Peer-Reviewed Original ResearchActive surveillanceProstate cancerProstate MRIPatient experienceGleason Grade Group 1Prostate cancer active surveillanceIntermediate-risk prostate cancerRisk prostate cancerGrade group 1Group 2 tumorsMRI-ultrasound fusion biopsyMean sample ageHispanics/LatinosInitial diagnosisFusion biopsyProstate biopsyConventional content analysisPatient's perspectiveClinical careGroup 1MRI resultsMRI scansProviders' explanationsCancerPatientsUse of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation
Leapman M, Wang R, Loeb S, Seibert T, Gaylis F, Lowentritt B, Brown G, Chen R, Lin D, Witte J, Cooperberg M, Catalona W, Gross C, Ma X. Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation. Journal Of Urology 2023, 209: 710-718. PMID: 36753746, DOI: 10.1097/ju.0000000000003159.Peer-Reviewed Original ResearchConceptsIntermediate-risk prostate cancerMixed-effects Poisson regressionPSA testingProstate biopsyProstate cancerEffects Poisson regressionMedicare beneficiariesPoisson regressionAdditional prostate biopsyRetrospective cohort studyProstate MRILocalized prostate cancerRepeat prostate biopsyRate of biopsyRace/ethnicityCensus tract povertyMedian followCohort studyMedian ageMonitoring testsProvider factorsPSA testClinical riskBiopsySociodemographic factors
2022
Parent Priorities in End-of-Life Care for Children with Cancer
Ananth P, Mun S, Lindsay M, De Oliveira S, Pitafi S, Ma X, Gross C, Boyden J, Feudtner C, Wolfe J. Parent Priorities in End-of-Life Care for Children with Cancer. Journal Of Pain And Symptom Management 2022, 63: 885. DOI: 10.1016/j.jpainsymman.2022.02.087.Peer-Reviewed Original ResearchMP53-11 FOUR KALLIKREIN PANEL TESTING AMONG MEDICARE BENEFICIARIES UNDERGOING PROSTATE CANCER SCREENING
Leapman M, Long J, Wang R, Sprenkle P, Ma X, Gross C. MP53-11 FOUR KALLIKREIN PANEL TESTING AMONG MEDICARE BENEFICIARIES UNDERGOING PROSTATE CANCER SCREENING. Journal Of Urology 2022, 207: e899. DOI: 10.1097/ju.0000000000002628.11.Peer-Reviewed Original Research